Literature DB >> 3907900

Human monoclonal antibodies from patients with rheumatoid arthritis: cross reactions against cellular constituents.

D O Haskard, V Gul, A Morgan, P Kataaha, N A Staines, J R Archer.   

Abstract

Hybridization of peripheral blood lymphocytes from patients with rheumatoid arthritis has yielded 14 monoclonal antibodies which react with cultured human epithelial cells. Immunofluorescence staining identifies at last five different types of antibody. Solid phase immunosorbent assays show a variety of cross-reaction patterns with nucleic acids, proteoglycan, cardiolipin and plastic, confirming that the various antibodies react with epitopes which are at least slightly different. These conclusions are confirmed by SDS gel electrophoresis and immunoblotting on epithelial cell extracts. Similar antibodies previously found in association with lupus-like disease have been thought to be representative of the high antinuclear antibody response characteristic of lupus. Our data are more consistent with the hypothesis that all or many of these antibodies are part of the normal inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3907900      PMCID: PMC1577268     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  All classes of intermediate filaments share a common antigenic determinant defined by a monoclonal antibody.

Authors:  R M Pruss; R Mirsky; M C Raff; R Thorpe; A J Dowding; B H Anderton
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

Review 2.  The detection of human antibodies against cytoskeletal components.

Authors:  P Kurki; I Virtanen
Journal:  J Immunol Methods       Date:  1984-03-16       Impact factor: 2.303

3.  Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies.

Authors:  J André-Schwartz; S K Datta; Y Shoenfeld; D A Isenberg; B D Stollar; R S Schwartz
Journal:  Clin Immunol Immunopathol       Date:  1984-05

4.  Multiple autoantigen binding capabilities of mouse monoclonal antibodies selected for rheumatoid factor activity.

Authors:  R L Rubin; R S Balderas; E M Tan; F J Dixon; A N Theofilopoulos
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

5.  Purification of fibronectin from human plasma by affinity chromatography under non-denaturing conditions.

Authors:  M Vuento; A Vaheri
Journal:  Biochem J       Date:  1979-11-01       Impact factor: 3.857

6.  Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas.

Authors:  Y Shoenfeld; J Rauch; H Massicotte; S K Datta; J André-Schwartz; B D Stollar; R S Schwartz
Journal:  N Engl J Med       Date:  1983-02-24       Impact factor: 91.245

7.  Cross-reactivity of anti-DNA antibodies with proteoglycans.

Authors:  P Faaber; P J Capel; G P Rijke; G Vierwinden; L B van de Putte; R A Koene
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

8.  Collagen-induced arthritis in the rat: modification of immune and arthritic responses by free collagen and immune anti-collagen antiserum.

Authors:  N A Staines; T Hardingham; M Smith; B Henderson
Journal:  Immunology       Date:  1981-12       Impact factor: 7.397

9.  Cartilage proteoglycans. Structure and heterogeneity of the protein core and the effects of specific protein modifications on the binding to hyaluronate.

Authors:  T E Hardingham; R J Ewins; H Muir
Journal:  Biochem J       Date:  1976-07-01       Impact factor: 3.857

10.  Monoclonal antibodies provide specific intramolecular markers for the study of epithelial tonofilament organization.

Authors:  E B Lane
Journal:  J Cell Biol       Date:  1982-03       Impact factor: 10.539

View more
  1 in total

1.  Organ-specific autoantibodies in non-organ-specific autoimmune diseases with special reference to rheumatoid arthritis.

Authors:  P Youinou; W Mangold; J Jouquan; H Swirsky; P Le Goff; W A Scherbaum
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.